Immediate Impact
1 from Science/Nature 50 standout
Citing Papers
The hallmarks of cancer immune evasion
2024 Standout
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
2024 Standout
Works of Anne O’Dea being referenced
A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial.
2022
Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer.
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Anne O’Dea | 424 | 221 | 193 | 41 | 677 | |
| Barbara Brouwers | 328 | 182 | 96 | 32 | 677 | |
| L. E. Shepherd | 528 | 305 | 184 | 42 | 788 | |
| Domenico Sergi | 349 | 152 | 162 | 54 | 766 | |
| WJ Gradishar | 436 | 210 | 90 | 48 | 705 | |
| Lola Anagnostaki | 424 | 307 | 103 | 38 | 845 | |
| N.J. Bundred | 475 | 192 | 90 | 38 | 820 | |
| Simon B. Zeichner | 365 | 167 | 164 | 32 | 684 | |
| P. Neven | 516 | 218 | 188 | 24 | 815 | |
| Clarence B. Vaughn | 346 | 233 | 128 | 39 | 661 | |
| Parvin F. Peddi | 392 | 148 | 192 | 28 | 635 |
All Works
Loading papers...